EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ ALARM” study

Sofia Agelaki, Ioannis Boukovinas, Ilias Athanasiadis, Georgios Trimis, Ioannis Dimitriadis, Lazaros Poughias, Edith Morais, Ugne Sabale, Goran Bencina, Charalampos Athanasopoulos iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.6916 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Medicine, 2024. Verfasst von Sofia Agelaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Oncology, School of Medicine, University of Crete, Herakleion, Greece. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Human Papillomavirus Viruses, Oropharyngeal Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of this systematic literature review was to provide updated information on human papillomavirus (HPV) prevalence in locally and regionally advanced (LA) and recurrent/metastatic (RM) head and neck cancer (HNC) worldwide.

Methods

Electronic searches were conducted on clinicaltrials.gov , MEDLINE/PubMed, Embase, and ASCO/ESMO journals of congresses for interventional studies (IS; Phase I–III trials) as well as MEDLINE and Embase for non‐interventional studies (NIS) of LA/RM HNC published between January 01, 2010 and December 31, 2020. Criteria for study selection included: availability of HPV prevalence data for LA/RM HNC patients, patient enrollment from January 01, 2010 onward, and oropharyngeal cancer (OPC) included among HNC types. HPV prevalence per study was calculated as proportion of HPV+ over total number of enrolled patients. For overall HPV prevalence across studies, mean of reported HPV prevalence rates across studies and pooled estimate (sum of all HPV+ patients over sum of all patients enrolled) were assessed.

Results

Eighty‐one studies (62 IS; 19 NIS) were included, representing 9607 LA/RM HNC cases, with an overall mean (pooled) HPV prevalence of 32.6% (25.1%). HPV prevalence was 44.7% (44.0%) in LA and 24.3% (18.6%) in RM. Among 2714 LA/RM OPC patients from 52 studies with available data, mean (pooled) value was 55.8% (50.7%). The majority of data were derived from Northern America and Europe, with overall HPV prevalence of 46.0% (42.1%) and 24.7% (25.3%) across studies conducted exclusively in these geographic regions, respectively (Northern Europe: 31.9% [63.1%]). A “p16‐based” assay was the most frequently reported HPV detection methodology (58.0%).

Conclusion

Over the last decade, at least one quarter of LA/RM HNC and half of OPC cases studied in IS and NIS were HPV+. This alarming burden is consistent with a potential implication of HPV in the pathogenesis of at least a subgroup of HNC, underscoring the relevance of HPV testing and prophylaxis to HNC prevention and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsHuman Papillomavirus VirusesOropharyngeal NeoplasmsPapillomavirus InfectionsHumansNeoplasm Recurrence, LocalPapillomaviridaePrevalence

Stichwörter der Autor:innen

cancer preventioncancer risk factorsepidemiology and preventionhead and neck cancerviral oncology

Autor:innen und Institutionen

  • Laboratory of Translational Oncology, School of Medicine, University of Crete, Herakleion, Greece.
  • Department of Medical Oncology, University General Hospital of Herakleion, Herakleion, Greece.
  • Bioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece.
  • Department of Medical Oncology, Mitera Hospital, Athens, Greece.
  • MSD, Medical Affairs, Athens, Greece.
  • MSD, Center for Observational and Real-World Evidence (CORE), Lyon, France.

ORCID-Profile: Charalampos Athanasopoulos

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc., Rahway, NJ, USA

Zitieren

APA

Agelaki, S., Boukovinas, I., Athanasiadis, I., Trimis, G., Dimitriadis, I., Poughias, L., Morais, E., Sabale, U., Bencina, G., & Athanasopoulos, C. (2024). A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ ALARM” study. Cancer Medicine. https://doi.org/10.1002/cam4.6916

Vancouver

Agelaki S, Boukovinas I, Athanasiadis I, Trimis G, Dimitriadis I, Poughias L, et al. A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ ALARM” study. Cancer Medicine. 2024. doi:10.1002/cam4.6916

BibTeX
@article{Agelaki2024,
  author = {Agelaki, Sofia and Boukovinas, Ioannis and Athanasiadis, Ilias and Trimis, Georgios and Dimitriadis, Ioannis and Poughias, Lazaros and Morais, Edith and Sabale, Ugne and Bencina, Goran and Athanasopoulos, Charalampos},
  title = {A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ ALARM” study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6916}
}
Kostenlos starten →